Unambiguous disclosure without patent profanity (T 2171/21)
The IPKat
DECEMBER 20, 2023
US patent attorneys wishing to understand certain peculiarities of European patent drafting need look no further than the recent Board of Appeal decision in T 2171/21. The Novartis patent EP 3111954 in T 2171/21 related to the second medical use of the anti-IL-17 antibody secukinumab. 3d 1241 (Fed.
107 
Let's personalize your content